Skip to main content

Theranostics Licenses Biomarker Microdissection Tech from NIH

NEW YORK (GenomeWeb News) – Theranostics Health said today it has licensed proteomic biomarker discovery technology from the National Institutes of Health that was developed by the company’s founders.
 
The Rockville, Md.-based company’s core technology, Reverse Phase Protein Microarray combined with Laser Capture Microdissection, was developed by company co-founders Emanuel Petricoin and Lance Liotta.
 
Under the agreement, Theranostics will pay NIH license issue royalties, minimum annual royalties, and benchmark and earned royalties upon successful commercialization of the technology.
 
Petricoin, CSO of Theranostics, said in a statement that the company's “unique signaling pathway platform allows the activity of theranostic biomarkers of interest to be quantitatively measured from microdissected patient samples.”
 
Theranostics Health CEO Danong Chen said the exclusive license allows the company to develop companion diagnostics to be used in treatment decision-making and monitoring.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.